Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors on HPCs, rapidly mobilizing these cells from the bone marrow into the peripheral blood. In preclinical ...

The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309 ...

Irina Rabovetsky, CEO of A-Team Home Care Inc. About A-Team Home Care Inc.

CTD402’s ready-to-use manufacturing platform eliminates the 1-2 month delays inherent to autologous CAR-T therapies—delays that can be life-threatening for patients with rapidly progressive disease.

Jefferies, Leerink Partners and BofA Securities are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to ...

As Arcutis looks to continue to grow in this next chapter, we are delighted to welcome Amit, an exceptional and visionary biopharmaceutical leader, to the Arcutis Board,” said Frank Watanabe, ...

Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the proposed offering. LifeSci Capital ...

Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing s ...

In connection with the proposed offering, Vera Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the ...

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA–restricted, genetically unmodified allogeneic T cells. The ...

J.P. Morgan, TD Cowen and Piper Sandler acted as joint book-running managers of the offering. LifeSci Capital acted as a lead manager of the offering. H.C. Wainwright & Co. acted as a manager of the ...

The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...